SPORE Leukemia Tissue Bank
SPORE白血病组织库
基本信息
- 批准号:7715181
- 负责人:
- 金额:$ 11.47万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-07-01 至 2014-06-30
- 项目状态:已结题
- 来源:
- 关键词:Acute Lymphocytic LeukemiaAcute Myelocytic LeukemiaAnimal ModelArtsBasic ScienceBiologicalBiologyBiometryBloodBone MarrowCancer and Leukemia Group BCell LineCellsChronic Lymphocytic LeukemiaChronic Myeloid LeukemiaClinicalClinical DataClinical ProtocolsCollectionCommitCorrelative StudyDNADatabasesDysmyelopoietic SyndromesEnrollmentFundingGoalsHematologic NeoplasmsIndividualInstructionInvestigationJournalsLaboratoriesLaboratory FindingLeadershipMapsMolecularNational Cancer InstituteNormal tissue morphologyOhioOutcomePathologicPathologyPatientsPeer ReviewProcessPropertyProteinsPublishingRNAReproduction sporesResearchResearch InfrastructureResearch PersonnelResearch Project GrantsResearch SupportResourcesRoleSamplingSpecimenStructureTherapeuticTissue BankingTissue BanksTissue ProcurementsTissue SampleTissuesTranslatingTreatment ProtocolsUniversitiesValidationVertebral columnWorkbasebiomedical informaticsdata sharingexperiencehuman diseasehuman tissueinterestleukemialeukemia tissue bankpopulation basedrepositorysuccesstool
项目摘要
On order to successfully translate basic research in leukemia to the clinical setting, as well as to better
understand the relevance of observed clinical or population-based phenomena through laboratory-based
research, an extensive repository of tissue samples, with accompanying pathologic and clinical data, procured
from leukemia patients is necessary. To fulfill this role. Core A will provide researchers in the Leukemia SPORE
access to a relatively unprecedented repository of uniformly prepared and fully characterized leukemia patient
samples. The already well-established Ohio State University and CALGB Leukemia Tissue Banks (referred to
as SPORE LTBs) constitute the backbone of Core A, and contribute crucial experience and infrastructure to this
effort. The SPORE LTBs serves as centralized tissue banks of blood and bone marrow specimens, as well as
non-leukemic material, procured from leukemia patients enrolled on CALGB or OSU treatment protocols, and
provide these to investigators within and outside of OSU. This work will integrate with Cores B (biostatistics) and
C (Biomedical informatics) to maintain a detailed, current database of samples and accompanying clinical
information available. Beyond simply serving as a cell repository. Core A will perform regular validation of
sample quality, conduct molecular characterizations, and prepare derivatives (protein, DNA, RNA). The
availability of this infrastructure for procuring samples, and the large number of samples already in our
possession, will greatly facilitate the conduct of the research projects of this SPORE proposal as well as provide
an important and widely available resource for extended studies by investigators within this or outside the OSU
Leukemia SPORE. The specific aims of Core A are: (1) To provide central collection, processing and a state-of-
the-art repository for samples collected from leukemia patients treated on clinical protocols that are relevant to
the OSU Leukemia SPORE; (2) To provide materials from processed clinical samples to interested
investigators, within and outside of the OSU Leukemia SPORE, who examine relevant cellular and molecular
properties of leukemia and correlate these properties with clinical or population-based outcomes and who
commit to sharing the data derived from their research efforts. The effective collection and characterization of
leukemia samples by Core A and their provision to SPORE investigators is critical to the success of the research
proposed. The infrastructure of this Core A is therefore already in place, and partially supported through NCI
funding through both the CALGB and OSUCCC, In this Core proposal, we seek supplemental and not
overlapping funding for support ofthe SPORE projects
RELEVANCE (See instructions):
Biological mechanistic investigations rely on cell lines or animal models. While these are powerful research
tools, validating laboratory findings in human tissue is crucial to understand their relevance to human
disease. This Core will provide SPORE researchers with simplified access to a large repository of leukemia
patient samples and accompanying clinical information. This multi-tiered effort is essential to the overall goal
of this SPORE group to bring their findings to the practical benefit of patients with leukemia.
为了成功地将白血病的基础研究转化为临床环境,以及更好地
通过实验室了解观察到的临床或基于人群的现象的相关性
研究,一个广泛的组织样本储存库,以及伴随的病理和临床数据,采购
来自白血病患者的治疗是必要的。来完成这个角色。核心A将为研究人员提供白血病孢子
访问一个相对史无前例的统一准备和充分描述的白血病患者信息库
样本。已经建立良好的俄亥俄州立大学和CALGB白血病组织银行(参考
作为孢子LTB)构成了核心A的骨干,并为此贡献了关键的经验和基础设施
努力。孢子LTB是血液和骨髓标本的集中组织库,以及
非白血病材料,从参加CALGB或OSU治疗方案的白血病患者那里获得;以及
向俄亥俄州立大学内外的调查人员提供这些资料。这项工作将与核心B(生物统计)和
C(生物医学信息学)维护一个详细的、最新的样本和伴随临床的数据库
可用的信息。不仅仅是作为一个细胞储存库。核心A将定期执行以下验证
样品质量,进行分子表征,并准备衍生品(蛋白质,DNA,RNA)。这个
采购样品的基础设施的可用性,以及我们的
将极大地便利本孢子提案的研究项目的开展以及提供
一种重要的、广泛可用的资源,供OSU内部或外部的研究人员进行深入研究
白血病孢子。核心A的具体目标是:(1)提供中央收集、处理和状态-
从白血病患者采集的样本的-ART库,这些患者接受了与以下相关的临床方案的治疗
OSU白血病孢子;(2)向感兴趣的临床标本提供加工后的材料
OSU白血病孢子内外的研究人员,他们检查相关的细胞和分子
白血病的特征,并将这些特征与临床或基于人群的结局以及世卫组织
致力于共享从他们的研究工作中获得的数据。有效地收集和表征
核心A的白血病样本及其提供给孢子调查人员是研究成功的关键
建议。因此,此核心A的基础设施已经到位,并通过NCI提供部分支持
通过CALGB和OSUCCC提供资金,在本核心提案中,我们寻求补充而不是
支持孢子项目的重叠资金
相关性(请参阅说明):
生物机制研究依赖于细胞系或动物模型。虽然这些都是强有力的研究
工具,验证实验室在人体组织中的发现对于了解它们与人类的相关性至关重要
疾病。这一核心将为孢子研究人员提供对大型白血病存储库的简化访问
患者样本和伴随的临床信息。这种多层次的努力对总体目标至关重要。
将他们的发现带给白血病患者的实际利益。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GUIDO MARCUCCI其他文献
GUIDO MARCUCCI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GUIDO MARCUCCI', 18)}}的其他基金
The Role of miR-142 in the Transformation of Clonal Hematopoietic Disorders into AML
miR-142 在克隆性造血障碍转化为 AML 中的作用
- 批准号:
10367856 - 财政年份:2022
- 资助金额:
$ 11.47万 - 项目类别:
The Role of miR-142 in the Transformation of Clonal Hematopoietic Disorders into AML
miR-142 在克隆性造血障碍转化为 AML 中的作用
- 批准号:
10544734 - 财政年份:2022
- 资助金额:
$ 11.47万 - 项目类别:
Vascular Remodeling in the Bone Marrow Leukemic Niche: A Therapeutic Target?
骨髓白血病微环境中的血管重塑:治疗目标?
- 批准号:
10371023 - 财政年份:2020
- 资助金额:
$ 11.47万 - 项目类别:
Vascular Remodeling in the Bone Marrow Leukemic Niche: A Therapeutic Target?
骨髓白血病微环境中的血管重塑:治疗目标?
- 批准号:
10094210 - 财政年份:2020
- 资助金额:
$ 11.47万 - 项目类别:
Vascular Remodeling in the Bone Marrow Leukemic Niche: A Therapeutic Target?
骨髓白血病微环境中的血管重塑:治疗目标?
- 批准号:
10600088 - 财政年份:2020
- 资助金额:
$ 11.47万 - 项目类别:
Validation of microRNAs as therapeutic targets in hematological malignancies
验证 microRNA 作为血液恶性肿瘤治疗靶点
- 批准号:
8815267 - 财政年份:2011
- 资助金额:
$ 11.47万 - 项目类别:
Validation of microRNAs as therapeutic targets in hematological malignancies
验证 microRNA 作为血液恶性肿瘤治疗靶点
- 批准号:
8627134 - 财政年份:2011
- 资助金额:
$ 11.47万 - 项目类别:
Molecular characterization of normal cytogenetics AML in older patients
老年患者正常细胞遗传学 AML 的分子特征
- 批准号:
7471096 - 财政年份:2008
- 资助金额:
$ 11.47万 - 项目类别:
Molecular characterization of normal cytogenetics AML in older patients
老年患者正常细胞遗传学 AML 的分子特征
- 批准号:
7614313 - 财政年份:2008
- 资助金额:
$ 11.47万 - 项目类别:
Pharmacologic modulation of chromatin remodeling in leu*
leu* 染色质重塑的药理学调节
- 批准号:
7096021 - 财政年份:2005
- 资助金额:
$ 11.47万 - 项目类别:
相似海外基金
Computing analysis of leukemic stem cell dynamics in acute myelocytic leukemia
急性粒细胞白血病白血病干细胞动力学的计算分析
- 批准号:
19K08356 - 财政年份:2019
- 资助金额:
$ 11.47万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Generation of immunotoxins with super-targeting mAb in the acute myelocytic leukemia
在急性髓细胞白血病中使用超靶向单克隆抗体产生免疫毒素
- 批准号:
23501309 - 财政年份:2011
- 资助金额:
$ 11.47万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
DETERMINANTS OF RESPONSE OF ACUTE MYELOCYTIC LEUKEMIA
急性粒细胞白血病反应的决定因素
- 批准号:
3556971 - 财政年份:1980
- 资助金额:
$ 11.47万 - 项目类别:
DETERMINANTS OF RESPONSE OF ACUTE MYELOCYTIC LEUKEMIA
急性粒细胞白血病反应的决定因素
- 批准号:
3556968 - 财政年份:1980
- 资助金额:
$ 11.47万 - 项目类别:
ERADICATION OF ACUTE MYELOCYTIC LEUKEMIA CELLS BY MAB THERAPY
通过 MAB 疗法根除急性粒细胞白血病细胞
- 批准号:
3889304 - 财政年份:
- 资助金额:
$ 11.47万 - 项目类别: